News and Announcements
The Difference Between Crowdfunding Versus HNW Investors
- Published December 20, 2022 1:21AM UTC
- Publisher Leila Oliveira
- Categories Capital Raising Tips
Crowdfunding vs HNW investors
Which one to choose?
I hear this question a lot, so here’s a quick summary 👇
– Crowdfunding: Investors are normally users of the product.
– HNW: do not only provide money. They are often successful entrepreneurs themselves, which means they are in the perfect position to give you advice.
– Crowdfunding: Check sizes around $1000
– HNW: Check sizes from $25K up to $250K
– Crowdfunding: It doesn’t have to be equity-based.
– HNW: You give away equity and have the investor with you in the long run.
In conclusion:
🎯 Go for crowdfunding if you have a working prototype and enough capital (or a large enough audience) to give your campaign the needed initial traction.
🎯 Go for HNW investors if you think you would benefit from mentorship and connections and if you have the right kind of scalable business to attract angels.
Click here to view the original Linkedin post.
Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.
Your capital engagement platform
With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.
Capital Raising Tips
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
